Multiple sclerosis clinical trials

Explore recruiting multiple sclerosis clinical trials.

Recruiting multiple sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Multiple sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis

Spain, Poland, Portugal, Italy, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis

Netherlands, Germany, Denmark, Poland, Czechia, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS): a randomized controlled trial

Netherlands

Phase III and phase IV (Integrated) EU CTIS Study details

EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With Multiple Progressive Primary Sclerosis (MELATOMS)

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Randomized Autologous heMatopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis (RAM-MS)

Netherlands, Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multiple sclerosis trials by city

Multiple sclerosis in Toronto Multiple sclerosis in Vancouver Multiple sclerosis in Montreal Multiple sclerosis in Calgary Multiple sclerosis in Edmonton Multiple sclerosis in Ottawa Multiple sclerosis in Winnipeg Multiple sclerosis in Quebec City Multiple sclerosis in Hamilton Multiple sclerosis in Kitchener Multiple sclerosis in London Multiple sclerosis in Halifax Multiple sclerosis in New York Multiple sclerosis in Los Angeles Multiple sclerosis in Chicago Multiple sclerosis in Houston

Other conditions

Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease IgA nephropathy Polycystic kidney disease Migraine Alzheimer's disease Parkinson's disease Epilepsy ALS Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Dementia Depression Anxiety Bipolar disorder Schizophrenia PTSD